Zai Lab Ltd (ZLAB) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The Zai Lab Ltd. (ZLAB) study, officially titled “A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors,” aims to test a new cancer drug in advanced solid tumors. It seeks early signals on safety and anti-tumor activity, which could shape Zai Lab’s future oncology pipeline value.
The intervention is a single experimental drug called ZL-1310, given on its own as a treatment. It is designed to slow or shrink solid tumors that have limited options, positioning it as a potential new asset in Zai Lab’s cancer portfolio.
The trial is an interventional Phase 1b/2 study with one treatment arm and no randomization, so all patients receive ZL-1310. It is open-label and not blinded, and the main goal is to evaluate treatment impact and safety in real patients rather than compare against a control.
The study started recruiting after submission on February 24, 2025, marking the formal launch of clinical work. The latest update on February 10, 2026, shows the trial is still active, but primary and final completion dates are not yet posted, underscoring that data readouts remain in the future.
For investors, this update signals that Zai Lab continues to invest in early-stage oncology, which can support long-term growth expectations but also carries high trial risk. Progress here may influence sentiment on ZLAB’s innovation story versus global oncology peers, yet stock impact will likely stay muted until first efficacy or safety data emerge.
The study remains ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about ZLAB’s potential, visit the Zai Lab Ltd drug pipeline page.